Regenxbio (RGNX) Net Cash Flow (2014 - 2025)

Regenxbio's Net Cash Flow history runs 12 years deep, the most recent figure standing at -$24.3 million for Q4 2025.

• On a quarterly basis, Net Cash Flow fell 2777.23% year-over-year to -$24.3 million in Q4 2025; TTM through Dec 2025 was -$23.1 million, a 200.24% decrease from a year earlier, with the FY2025 full-year figure at -$23.1 million, down 200.24% from the prior year.
• Net Cash Flow retreated to -$24.3 million in Q4 2025 per RGNX's latest filing, from -$20.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $117.5 million in Q4 2021 and bottomed at -$153.3 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$21.2 million (2022), against an average of -$15.2 million.
• Across the five-year window, Net Cash Flow sank 45476.7% in 2021 and surged 392.07% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $117.5 million in 2021, then slumped by 118.37% to -$21.6 million in 2022, then climbed by 13.17% to -$18.7 million in 2023, then surged by 104.85% to $909000.0 in 2024, then sank by 2777.23% to -$24.3 million in 2025.
• Per Business Quant, the three latest RGNX Net Cash Flow figures stand at -$24.3 million (Q4 2025), -$20.8 million (Q3 2025), and -$50.5 million (Q2 2025).